公开(公告)号：US20140316143A1

公开(公告)日：2014-10-23

申请号：US14253976

申请日：2014-04-16

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Datong Tang ,  Guoyou Xu ,  Xiaowen Peng ,  Lu Ying ,  Ce Wang ,  Hui Cao ,  Jiang Long ,  In Jong Kim ,  Guoqiang Wang ,  Yao-Ling Qiu ,  Yat Sun Or

IPC: C07D403/14

CPC classification number: C07D403/14

Abstract: The present invention relates to processes and intermediates for the preparation of novel benzimidazole derivatives, especially in the synthesis of hepatitis C virus NS5A inhibitors. In particular, the present invention relates to processes and intermediates for the preparation of compounds of formulae (I-a):

Abstract translation: 本发明涉及制备新型苯并咪唑衍生物的方法和中间体，特别是在丙型肝炎病毒NS5A抑制剂的合成中。 特别地，本发明涉及制备式（I-a）化合物的方法和中间体：

公开(公告)号：US20230159546A1

公开(公告)日：2023-05-25

申请号：US17989103

申请日：2022-11-17

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Jorden Kass ,  Wei Li ,  Hui Cao ,  Jiajun Zhang ,  Xuri Gao ,  Xiaowen Peng ,  Ruichao Shen ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10

CPC classification number: C07D487/10

Abstract: The present invention discloses compounds of Formula (Ia), and pharmaceutically acceptable salts thereof:




which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (Ia) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US20230115107A1

公开(公告)日：2023-04-13

申请号：US17720654

申请日：2022-04-14

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Xuri Gao ,  Wei Li ,  Jiajun Zhang ,  Xiaowen Peng ,  Hui Cao ,  Jorden Kass ,  Ruichao Shen ,  Guoqiang Wang ,  Yat Sun Or

IPC: C07D487/10 ,  C07D487/12 ,  A61P31/14

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US11596611B2

公开(公告)日：2023-03-07

申请号：US17166046

申请日：2021-02-03

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Jorden Kass ,  Hui Cao ,  Wei Li ,  Xiaowen Peng ,  Byung-Chul Suh ,  Yat Sun Or

IPC: A61K31/167 ,  A61K31/4164 ,  A61K31/34 ,  A61K31/357 ,  A61K31/4409 ,  A61K31/426 ,  A61K31/4015 ,  A61K31/4439 ,  A61K31/415 ,  A61K31/421 ,  A61K31/4192 ,  A61K31/351 ,  A61K31/397 ,  A61K31/337 ,  A61K31/47 ,  A61K31/513 ,  A61K31/7028 ,  A61P31/20 ,  A61K31/401 ,  C07C303/00 ,  C07C317/44 ,  A61K45/06

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20220162231A1

公开(公告)日：2022-05-26

申请号：US17531844

申请日：2021-11-22

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Guoqiang Wang ,  Ruichao Shen ,  Jun Ma ,  Yong He ,  Xuechao Xing ,  Hui Cao ,  Xuri Gao ,  Xiaowen Peng ,  Joseph D. Panarese ,  Yat Sun Or

IPC: C07D519/00

Abstract: The present invention discloses compounds of Formula (I), and pharmaceutically acceptable salts, thereof: which inhibit coronavirus replication activity. The invention further relates to pharmaceutical compositions comprising a compound of Formula (I) or a pharmaceutically acceptable salt thereof, and methods of treating or preventing a coronavirus infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Formula (I) or a pharmaceutically acceptable salt thereof.

公开(公告)号：US10738035B2

公开(公告)日：2020-08-11

申请号：US15152647

申请日：2016-05-12

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yao-Ling Qiu ,  Wei Li ,  Hui Cao ,  Meizhong Jin ,  Xuri Gao ,  Xiaowen Peng ,  Jorden Kass ,  Yat Sun Or

IPC: C07D405/12 ,  A61K31/454 ,  A61K45/06 ,  C07D231/38 ,  C07D403/12 ,  C07D211/46 ,  A61K31/445 ,  C07D401/14 ,  C07D231/40 ,  C07D401/12 ,  A61K31/415 ,  A61K31/4155 ,  A61K31/5377 ,  A61K31/4545

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y—Z-L-R1  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US10538532B2

公开(公告)日：2020-01-21

申请号：US16194608

申请日：2018-11-19

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Wei Li ,  Hui Cao ,  Meizhong Jin ,  Jorden Kass ,  Xiaowen Peng ,  Yat Sun Or

IPC: C07D493/08 ,  A61K31/167 ,  A61K31/18 ,  A61K31/196 ,  A61K31/215 ,  A61K31/223 ,  A61K31/277 ,  A61K31/325 ,  A61K31/335 ,  A61K31/336 ,  A61K31/341 ,  A61K31/351 ,  A61K31/357 ,  A61K31/365 ,  A61K31/39 ,  A61K31/401 ,  A61K31/41 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4164 ,  A61K31/421 ,  A61K31/426 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4409 ,  A61K31/4425 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/655 ,  C07B59/00 ,  C07C235/56 ,  C07C311/53 ,  C07C317/32 ,  C07C323/42 ,  C07D207/16 ,  C07D211/54 ,  C07D213/52 ,  C07D213/81 ,  C07D213/89 ,  C07D231/12 ,  C07D233/64 ,  C07D257/04 ,  C07D261/02 ,  C07D261/08 ,  C07D261/20 ,  C07D263/52 ,  C07D277/26 ,  C07D295/088 ,  C07D303/26 ,  C07D303/34 ,  C07D307/32 ,  C07D307/33 ,  C07D309/08 ,  C07D313/04 ,  C07D317/72 ,  C07D327/10 ,  C07D401/04 ,  C07D451/04 ,  C07D493/04 ,  C07C317/44 ,  C07C323/62

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US10280175B2

公开(公告)日：2019-05-07

申请号：US15421777

申请日：2017-02-01

Applicant: Enanta Pharmaceuticals, Inc.

Inventor： Yat Sun Or ,  Meizhong Jin ,  Jorden Kass ,  Hui Cao ,  Xuri Gao ,  Wei Li ,  Xiaowen Peng ,  Yao-Ling Qiu

IPC: C07D487/10 ,  A61K31/4178 ,  A61K31/435 ,  A61K31/438 ,  A61K31/46 ,  C07D221/20 ,  C07D403/12 ,  C07D451/02 ,  C07D451/06 ,  C07D471/10

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y—Z—R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US20190084994A1

公开(公告)日：2019-03-21

申请号：US16194608

申请日：2018-11-19

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Xuri Gao ,  Wei Li ,  Hui Cao ,  Meizhong Jin ,  Jorden Kass ,  Xiaowen Peng ,  Yat Sun Or

IPC: C07D493/08 ,  C07D493/04 ,  C07D451/04 ,  C07D401/04 ,  C07D327/10 ,  C07D317/72 ,  C07D313/04 ,  C07D309/08 ,  C07D307/33 ,  C07D307/32 ,  C07D303/34 ,  C07D303/26 ,  C07D295/088 ,  C07D277/26 ,  C07D263/52 ,  C07D261/20 ,  C07D261/08 ,  C07D261/02 ,  C07D257/04 ,  C07D233/64 ,  C07D231/12 ,  C07D213/89 ,  C07D213/81 ,  C07D213/52 ,  C07D211/54 ,  C07D207/16 ,  C07C235/56 ,  C07B59/00 ,  C07C323/62 ,  C07C317/44 ,  C07C323/42 ,  C07C317/32 ,  C07C311/53 ,  A61K31/655 ,  A61K31/5377 ,  A61K31/4545 ,  A61K31/445 ,  A61K31/4425 ,  A61K31/4409 ,  A61K31/4402 ,  A61K31/44 ,  A61K31/439 ,  A61K31/426 ,  A61K31/421 ,  A61K31/4164 ,  A61K31/416 ,  A61K31/415 ,  A61K31/41 ,  A61K31/401 ,  A61K31/39 ,  A61K31/365 ,  A61K31/357 ,  A61K31/351 ,  A61K31/341 ,  A61K31/336 ,  A61K31/335 ,  A61K31/325 ,  A61K31/277 ,  A61K31/223 ,  A61K31/215 ,  A61K31/196 ,  A61K31/18 ,  A61K31/167

CPC classification number: C07D493/08 ,  A61K31/167 ,  A61K31/18 ,  A61K31/196 ,  A61K31/215 ,  A61K31/223 ,  A61K31/277 ,  A61K31/325 ,  A61K31/335 ,  A61K31/336 ,  A61K31/341 ,  A61K31/351 ,  A61K31/357 ,  A61K31/365 ,  A61K31/39 ,  A61K31/401 ,  A61K31/41 ,  A61K31/415 ,  A61K31/416 ,  A61K31/4164 ,  A61K31/421 ,  A61K31/426 ,  A61K31/439 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4409 ,  A61K31/4425 ,  A61K31/445 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/655 ,  C07B59/001 ,  C07B2200/05 ,  C07B2200/07 ,  C07C235/56 ,  C07C311/53 ,  C07C317/32 ,  C07C317/44 ,  C07C323/42 ,  C07C323/62 ,  C07C2601/04 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2601/16 ,  C07C2601/18 ,  C07C2602/44 ,  C07C2602/46 ,  C07C2603/74 ,  C07D207/16 ,  C07D211/54 ,  C07D213/52 ,  C07D213/81 ,  C07D213/89 ,  C07D231/12 ,  C07D233/64 ,  C07D257/04 ,  C07D261/02 ,  C07D261/08 ,  C07D261/20 ,  C07D263/52 ,  C07D277/26 ,  C07D295/088 ,  C07D303/26 ,  C07D303/34 ,  C07D307/32 ,  C07D307/33 ,  C07D309/08 ,  C07D313/04 ,  C07D317/72 ,  C07D327/10 ,  C07D401/04 ,  C07D451/04 ,  C07D493/04

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-L-R  (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

公开(公告)号：US10189846B2

公开(公告)日：2019-01-29

申请号：US15617445

申请日：2017-06-08

Applicant: ENANTA PHARMACEUTICALS, INC.

Inventor： Yao-Ling Qiu ,  Hui Cao ,  Xiaowen Peng ,  Wei Li ,  Jorden Kass ,  Xuri Gao ,  Meizhong Jin ,  Yat Sun Or

IPC: A61K31/519 ,  C07D487/04 ,  A61P31/20 ,  A61K45/06

Abstract: The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, thereof: which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.